These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 38015466)

  • 1. Interrogating two extensively self-targeting Type I CRISPR-Cas systems in Xanthomonas albilineans reveals distinct anti-CRISPR proteins that block DNA degradation.
    Wimmer F; Englert F; Wandera KG; Alkhnbashi OS; Collins SP; Backofen R; Beisel CL
    Nucleic Acids Res; 2024 Jan; 52(2):769-783. PubMed ID: 38015466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR RNA and anti-CRISPR protein binding to the
    Hong S; Ka D; Yoon SJ; Suh N; Jeong M; Suh JY; Bae E
    J Biol Chem; 2018 Feb; 293(8):2744-2754. PubMed ID: 29348170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cas3 is a limiting factor for CRISPR-Cas immunity in Escherichia coli cells lacking H-NS.
    Majsec K; Bolt EL; Ivančić-Baće I
    BMC Microbiol; 2016 Mar; 16():28. PubMed ID: 26956996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance and Processing of Foreign DNA by the Escherichia coli CRISPR-Cas System.
    Redding S; Sternberg SH; Marshall M; Gibb B; Bhat P; Guegler CK; Wiedenheft B; Doudna JA; Greene EC
    Cell; 2015 Nov; 163(4):854-65. PubMed ID: 26522594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cas3-Derived Target DNA Degradation Fragments Fuel Primed CRISPR Adaptation.
    Künne T; Kieper SN; Bannenberg JW; Vogel AI; Miellet WR; Klein M; Depken M; Suarez-Diez M; Brouns SJ
    Mol Cell; 2016 Sep; 63(5):852-64. PubMed ID: 27546790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type I-E CRISPR-cas systems discriminate target from non-target DNA through base pairing-independent PAM recognition.
    Westra ER; Semenova E; Datsenko KA; Jackson RN; Wiedenheft B; Severinov K; Brouns SJ
    PLoS Genet; 2013; 9(9):e1003742. PubMed ID: 24039596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining the Specificity of Cascade Binding, Interference, and Primed Adaptation
    Cooper LA; Stringer AM; Wade JT
    mBio; 2018 Apr; 9(2):. PubMed ID: 29666291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioinformatics Identification of Anti-CRISPR Loci by Using Homology, Guilt-by-Association, and CRISPR Self-Targeting Spacer Approaches.
    Yin Y; Yang B; Entwistle S
    mSystems; 2019 Sep; 4(5):. PubMed ID: 31506266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic mechanisms of CRISPR interference by Escherichia coli CRISPR-Cas3.
    Yoshimi K; Takeshita K; Kodera N; Shibumura S; Yamauchi Y; Omatsu M; Umeda K; Kunihiro Y; Yamamoto M; Mashimo T
    Nat Commun; 2022 Aug; 13(1):4917. PubMed ID: 36042215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Cas6e ribonuclease is not required for interference and adaptation by the E. coli type I-E CRISPR-Cas system.
    Semenova E; Kuznedelov K; Datsenko KA; Boudry PM; Savitskaya EE; Medvedeva S; Beloglazova N; Logacheva M; Yakunin AF; Severinov K
    Nucleic Acids Res; 2015 Jul; 43(12):6049-61. PubMed ID: 26013814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural Variation of Type I-F CRISPR RNA Guided DNA Surveillance.
    Pausch P; Müller-Esparza H; Gleditzsch D; Altegoer F; Randau L; Bange G
    Mol Cell; 2017 Aug; 67(4):622-632.e4. PubMed ID: 28781236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular insights into DNA interference by CRISPR-associated nuclease-helicase Cas3.
    Gong B; Shin M; Sun J; Jung CH; Bolt EL; van der Oost J; Kim JS
    Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16359-64. PubMed ID: 25368186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fidelity of prespacer capture and processing is governed by the PAM-mediated interactions of Cas1-2 adaptation complex in CRISPR-Cas type I-E system.
    Yoganand KN; Muralidharan M; Nimkar S; Anand B
    J Biol Chem; 2019 Dec; 294(52):20039-20053. PubMed ID: 31748409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CRISPR AcrIE2 Binds the Type I-E CRISPR-Cas Complex But Does Not Block DNA Binding.
    Mejdani M; Pawluk A; Maxwell KL; Davidson AR
    J Mol Biol; 2021 Feb; 433(3):166759. PubMed ID: 33338493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cas9 function and host genome sampling in Type II-A CRISPR-Cas adaptation.
    Wei Y; Terns RM; Terns MP
    Genes Dev; 2015 Feb; 29(4):356-61. PubMed ID: 25691466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct Subcellular Localization of a Type I CRISPR Complex and the Cas3 Nuclease in Bacteria.
    Govindarajan S; Borges A; Karambelkar S; Bondy-Denomy J
    J Bacteriol; 2022 May; 204(5):e0010522. PubMed ID: 35389256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition Mechanism of an Anti-CRISPR Suppressor AcrIIA4 Targeting SpyCas9.
    Yang H; Patel DJ
    Mol Cell; 2017 Jul; 67(1):117-127.e5. PubMed ID: 28602637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spacer-length DNA intermediates are associated with Cas1 in cells undergoing primed CRISPR adaptation.
    Musharova O; Klimuk E; Datsenko KA; Metlitskaya A; Logacheva M; Semenova E; Severinov K; Savitskaya E
    Nucleic Acids Res; 2017 Apr; 45(6):3297-3307. PubMed ID: 28204574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA interference is controlled by R-loop length in a type I-F1 CRISPR-Cas system.
    Tuminauskaite D; Norkunaite D; Fiodorovaite M; Tumas S; Songailiene I; Tamulaitiene G; Sinkunas T
    BMC Biol; 2020 Jun; 18(1):65. PubMed ID: 32539804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA targeting by the type I-G and type I-A CRISPR-Cas systems of Pyrococcus furiosus.
    Elmore J; Deighan T; Westpheling J; Terns RM; Terns MP
    Nucleic Acids Res; 2015 Dec; 43(21):10353-63. PubMed ID: 26519471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.